Illumina, Inc. (ETR:ILU)

Market Cap	14.28B
Revenue (ttm)	4.19B
Net Income (ttm)	-1.17B
Shares Out	n/a
EPS (ttm)	-7.38
PE Ratio	n/a
Forward PE	n/a
Dividend	2.89 (2.93%)
Ex-Dividend Date	n/a

Volume	26
Average Volume	433
Open	98.39
Previous Close	98.41
Day's Range	98.39 - 98.86
52-Week Range	93.00 - 150.56
Beta	1.13
RSI	23.24
Earnings Date	Feb 7, 2025

About Illumina

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1998
• Employees: 9,030
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ILU

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Financial numbers in USD